drugset / Trial / NCT06536010
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
NaSingle-groupOpen-labelTreatment
Summary
This is a clinical efficacy study evaluating the VAG regimen in the treatment of newly diagnosed acute myeloid leukemia (AML). The main objectives of the study are to assess the efficacy and safety of the VAG regimen and to explore the synergistic mechanisms of VAG in combating AML.
Timeline
- Start
- 2021-11-03
- Primary completion
- 2026-07-31
- Completion
- 2028-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |